Oxytocin, the panacea for long-COVID? a review
© 2022 Walter de Gruyter GmbH, Berlin/Boston..
OBJECTIVES: In this hypothesis paper we explore the underlying mechanisms for long-COVID and how the oxytocinergic neurones could be infected by SARS-CoV-2 leading to a reduction in plasma oxytocin (OXT). Furthermore, we aim to review the relevance of OXT and hypothalamic function in recovery from long-COVID symptoms and pathology, through exploring the pro-health effects of the OXT neuropeptide.
METHODS: A review of published literature was surveyed using Google Scholar and PubMed.
RESULTS: Numerous experimental data can be shown to correlate with OXT and long-COVID symptoms and conditions, thus providing strong circumstantial evidence to support our hypothesis. It is postulated that the reduction in plasma OXT due to acute and post-viral damage to the hypothalamus and oxytocinergic neurones contributes to the variable multi-system, remitting and relapsing nature of long-COVID. The intranasal route of OXT application was determined to be most appropriate and clinically relevant for the restoration of oxytocinergic function post COVID-19 infection.
CONCLUSIONS: We believe it is imperative to further investigate whether OXT alleviates the prolonged suffering of patients with long-COVID. Succinctly, OXT may be the much-needed post-pandemic panacea.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:43 |
|---|---|
| Enthalten in: |
Hormone molecular biology and clinical investigation - 43(2022), 3 vom: 01. Sept., Seite 363-371 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Diep, Phuoc-Tan [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
50-56-6 |
|---|
| Anmerkungen: |
Date Completed 30.09.2022 Date Revised 07.12.2022 published: Electronic-eCollection Citation Status MEDLINE |
|---|
| doi: |
10.1515/hmbci-2021-0034 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM34099455X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM34099455X | ||
| 003 | DE-627 | ||
| 005 | 20231226010738.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1515/hmbci-2021-0034 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1136.xml |
| 035 | |a (DE-627)NLM34099455X | ||
| 035 | |a (NLM)35576613 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Diep, Phuoc-Tan |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Oxytocin, the panacea for long-COVID? a review |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 30.09.2022 | ||
| 500 | |a Date Revised 07.12.2022 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2022 Walter de Gruyter GmbH, Berlin/Boston. | ||
| 520 | |a OBJECTIVES: In this hypothesis paper we explore the underlying mechanisms for long-COVID and how the oxytocinergic neurones could be infected by SARS-CoV-2 leading to a reduction in plasma oxytocin (OXT). Furthermore, we aim to review the relevance of OXT and hypothalamic function in recovery from long-COVID symptoms and pathology, through exploring the pro-health effects of the OXT neuropeptide | ||
| 520 | |a METHODS: A review of published literature was surveyed using Google Scholar and PubMed | ||
| 520 | |a RESULTS: Numerous experimental data can be shown to correlate with OXT and long-COVID symptoms and conditions, thus providing strong circumstantial evidence to support our hypothesis. It is postulated that the reduction in plasma OXT due to acute and post-viral damage to the hypothalamus and oxytocinergic neurones contributes to the variable multi-system, remitting and relapsing nature of long-COVID. The intranasal route of OXT application was determined to be most appropriate and clinically relevant for the restoration of oxytocinergic function post COVID-19 infection | ||
| 520 | |a CONCLUSIONS: We believe it is imperative to further investigate whether OXT alleviates the prolonged suffering of patients with long-COVID. Succinctly, OXT may be the much-needed post-pandemic panacea | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a action mechanism | |
| 650 | 4 | |a hypothalamus | |
| 650 | 4 | |a long-COVID | |
| 650 | 4 | |a oxytocin | |
| 650 | 7 | |a Neuropeptides |2 NLM | |
| 650 | 7 | |a Oxytocin |2 NLM | |
| 650 | 7 | |a 50-56-6 |2 NLM | |
| 700 | 1 | |a Chaudry, Mohammed |e verfasserin |4 aut | |
| 700 | 1 | |a Dixon, Adam |e verfasserin |4 aut | |
| 700 | 1 | |a Chaudry, Faisal |e verfasserin |4 aut | |
| 700 | 1 | |a Kasabri, Violet |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Hormone molecular biology and clinical investigation |d 2010 |g 43(2022), 3 vom: 01. Sept., Seite 363-371 |w (DE-627)NLM205276490 |x 1868-1891 |7 nnns |
| 773 | 1 | 8 | |g volume:43 |g year:2022 |g number:3 |g day:01 |g month:09 |g pages:363-371 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1515/hmbci-2021-0034 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 43 |j 2022 |e 3 |b 01 |c 09 |h 363-371 | ||